Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma.
Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.
Written by:
Roos FC. Are you the author?
Department of Urology, Medical School, Johannes Gutenberg University, Langenbeckstrasse 1, Mainz 55131, Germany.
Reference: Nat Rev Urol. 2014 Jun;11(6):315-6.
doi: 10.1038/nrurol.2014.120
PubMed Abstract
PMID: 24890884
UroToday.com Renal Cancer Section
